Charles Schwab Investment Management Inc. Has $113.02 Million Holdings in Bio-Techne Co. (NASDAQ:TECH)

Charles Schwab Investment Management Inc. cut its stake in shares of Bio-Techne Co. (NASDAQ:TECH - Free Report) by 5.9% in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 1,414,003 shares of the biotechnology company's stock after selling 88,911 shares during the period. Charles Schwab Investment Management Inc. owned about 0.89% of Bio-Techne worth $113,021,000 as of its most recent SEC filing.

A number of other large investors also recently modified their holdings of the company. CANADA LIFE ASSURANCE Co raised its position in Bio-Techne by 8.2% in the first quarter. CANADA LIFE ASSURANCE Co now owns 58,798 shares of the biotechnology company's stock valued at $4,140,000 after purchasing an additional 4,457 shares during the last quarter. Silvercrest Asset Management Group LLC boosted its position in Bio-Techne by 28.6% during the 1st quarter. Silvercrest Asset Management Group LLC now owns 7,204 shares of the biotechnology company's stock worth $507,000 after buying an additional 1,600 shares during the period. Bayesian Capital Management LP acquired a new stake in Bio-Techne during the 1st quarter worth approximately $964,000. Janus Henderson Group PLC increased its position in Bio-Techne by 1.3% in the 1st quarter. Janus Henderson Group PLC now owns 995,824 shares of the biotechnology company's stock valued at $70,095,000 after acquiring an additional 12,991 shares during the period. Finally, Tidal Investments LLC increased its position in Bio-Techne by 135.5% in the 1st quarter. Tidal Investments LLC now owns 31,990 shares of the biotechnology company's stock valued at $2,252,000 after acquiring an additional 18,404 shares during the period. 98.95% of the stock is currently owned by institutional investors.

Bio-Techne Trading Up 0.6 %

Shares of TECH stock traded up $0.48 during trading hours on Tuesday, hitting $74.87. 985,204 shares of the company were exchanged, compared to its average volume of 1,028,406. The company has a debt-to-equity ratio of 0.14, a quick ratio of 3.26 and a current ratio of 4.56. Bio-Techne Co. has a fifty-two week low of $61.16 and a fifty-two week high of $85.57. The company has a 50 day simple moving average of $73.76 and a two-hundred day simple moving average of $75.18. The firm has a market cap of $11.90 billion, a P/E ratio of 79.63, a P/E/G ratio of 5.20 and a beta of 1.28.

Bio-Techne (NASDAQ:TECH - Get Free Report) last posted its quarterly earnings results on Wednesday, October 30th. The biotechnology company reported $0.42 earnings per share for the quarter, beating the consensus estimate of $0.38 by $0.04. The firm had revenue of $289.46 million during the quarter, compared to the consensus estimate of $280.22 million. Bio-Techne had a net margin of 12.86% and a return on equity of 12.76%. The business's revenue was up 4.5% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.35 earnings per share. Equities analysts anticipate that Bio-Techne Co. will post 1.68 EPS for the current year.

Bio-Techne Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Friday, November 22nd. Investors of record on Monday, November 11th were paid a dividend of $0.08 per share. This represents a $0.32 dividend on an annualized basis and a yield of 0.43%. The ex-dividend date of this dividend was Friday, November 8th. Bio-Techne's dividend payout ratio (DPR) is currently 34.04%.

Analysts Set New Price Targets

Several brokerages recently weighed in on TECH. Benchmark reissued a "buy" rating and issued a $95.00 price objective on shares of Bio-Techne in a research note on Tuesday, August 13th. Robert W. Baird upped their price target on Bio-Techne from $82.00 to $84.00 and gave the company an "outperform" rating in a research report on Thursday, October 31st. StockNews.com upgraded Bio-Techne from a "hold" rating to a "buy" rating in a research report on Tuesday, November 12th. Scotiabank upped their target price on Bio-Techne from $83.00 to $88.00 and gave the company a "sector outperform" rating in a report on Thursday, October 31st. Finally, Royal Bank of Canada lowered their price target on shares of Bio-Techne from $72.00 to $70.00 and set a "sector perform" rating for the company in a report on Thursday, August 8th. Three investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to data from MarketBeat, Bio-Techne currently has a consensus rating of "Moderate Buy" and a consensus target price of $81.78.

Bio-Techne Company Profile

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets in the United States, the United Kingdom, rest of Europe, Middle East, and Africa, Greater China, rest of Asia-Pacific, and internationally.